Abstract: Objective To evaluate the clinical efficacy and prognosis in patients receiving ovarian function castration combined with aromatase inhibitors treatment for premenopausal metastatic breast cancer. Methods One hundred and forty hormone dependent mastatic breast cancer patients received ovarian function castration（ovarian resection surgery or goserelin） combined with aromatase inhibitors（anastrozole，letrozole or exemestane） were analyzed retrospectively. The clinical efficacy and prognosis of all patients were evaluated.
Results All the patients’ median progression free survival（PFS） was 8.0 months and the clinical benefit rate was 56.3％. The PFS of patients received firstline treatment and second-line or above were 9.0 months（95％CI：6.3-11.7） and 6.0 months（95％CI：4.1-7.9）， respectively； the clinical benefit rates of two groups were 66.7％， 39.7％； the median clinical benefit time were 13.1 months（95％CI：10.9-16.3） and 9.3 months（95％CI：6.8-11.8）.In subgroup analysis， the patients who had single organ metastasis， no visceral metastasis and nonreceived chemotherapy before obtained better curative effects. Cox regression analysis showed the number of metastatic position was independent factors of PFS.
ConclusionThe combination of ovarian function castration and aromatase inhibitors is effective endocrine therapy regiment with well-tolerated toxicity for patients with premenopausal metastatic breast cancer. It can be recommended as first-line therapy for the premenopausal and hormone dependent matastatic breast cancer patients.